Metronidazole Inhibitors
2 drugsAbout Metronidazole
Metronidazole is a nitroimidazole antibiotic targeting anaerobic bacteria and parasites. Its nitro group is reduced within susceptible cells, creating cytotoxic intermediates that damage DNA. This mechanism makes it a valuable drug target for treating a range of infections.
Metronidazole is a clinically validated target, evidenced by two FDA-approved drugs. However, there is currently no genetic evidence directly linking metronidazole's target to specific diseases.
Two FDA-approved drugs contain metronidazole: PYLERA and BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE. Both drugs are small molecules and are marketed by LABS JUVISE and PH HEALTH, respectively.
Top Metronidazole Drugs
The competitive landscape includes two companies with approved drugs: LABS JUVISE and PH HEALTH.
Low market concentration suggests relatively low barriers to entry for new competitors.
Metronidazole Drug Modality Landscape
Modalities
Routes of Administration
Metronidazole is amenable to small molecule drugs, with oral options available for convenient dosing.
The lack of diverse modalities represents a whitespace opportunity for novel therapeutic approaches like antibodies or biologics.
Metronidazole Clinical Trials 121 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Metronidazole. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 12 | 11 | 1 | 0 | 92% |
| Phase 2 | 28 | 16 | 2 | 10 | 89% |
| Phase 3 | 26 | 20 | 2 | 4 | 91% |
| Phase 4 | 55 | 40 | 7 | 8 | 85% |
Top Sponsors
By Modality
Top Conditions
Metronidazole Drug Approval Timeline (2006 - 2023)
Helicobacter pylori Infection
The first drug was approved in 2006 (PYLERA), with the most recent in 2023.
The 18-year span between approvals indicates a potentially slow-growing but persistent market.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 86 (18 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Metronidazole. A trial counts if an approved drug acting on Metronidazole is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.